繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 前列腺癌(睾丸癌,膀胱癌) >> 药品推荐 >> 卡介苗灌注剂(BCG vaccine,ONCOTICE)

卡介苗灌注剂(BCG vaccine,ONCOTICE)

2012-11-11 14:55:05  作者:新特药房  来源:互联网  浏览次数:261  文字大小:【】【】【
简介: Demonstrate that after complete transurethral resection of all papillary tumors, one third dose BCG (Bacillus Calmette-Guerin vaccine; OncoTICE) is equivalent to full dose BCG and sho ...
  1. Demonstrate that after complete transurethral resection of all papillary tumors, one third dose BCG (Bacillus Calmette-Guerin vaccine; OncoTICE) is equivalent to full dose BCG and short term maintenance is equivalent to long term maintenance with respect to duration of disease free interval, recurrence rate, percentage of patients with an increase in T-category to greater than T1, and the incidence of carcinoma in situ during follow-up.
  2. Demonstrate that one third dose BCG and short term maintenance are associated with fewer local and systemic side effects.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed transitional cell carcinoma of the bladder of the following types:
    • Multiple (not greater than 10), resectable, T1 or Ta, grade G1-G3
    • Solitary T1 GIII tumor

Prior/Concurrent Therapy:

Biologic therapy:

  • No prior treatment with BCG

Chemotherapy:

  • No cytostatic agents within the past 3 months

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Patient Characteristics:

Age:

  • 85 and under

Performance status:

  • WHO 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3

Hepatic:

  • Values used to evaluate function may not exceed two times the upper limit of normal

Renal:

  • Values used to evaluate function may not exceed two times the upper limit of normal

Other:

  • No second malignancy except basal cell skin carcinoma
  • Not pregnant or nursing
  • No uncontrollable urinary tract infection
  • No active tuberculosis
  • No HIV antibody
  • No leukemia
  • No Hodgkin's disease
  • No transplant recipients

Expected Enrollment

1288

1288 patients will be accrued for this study.

Outcomes

Primary Outcome(s)

Dose equivalency with respect to duration of disease free interval, recurrence rate, percentage of patients with an increase in T-category to greater than T1, and the incidence of carcinoma in situ during follow-up
Dose equivalency in terms of fewer local and systemic side effects

Outline

This is a prospective randomized study.

At 7-15 days after transurethral resection, patients will begin receiving one of the following four regimens:

  • Regimen 1: One third dose Bacillus Calmette-Guerin (BCG) vaccine plus short term maintenance. Patients receive a one third dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, and 12.

  • Regimen 2: Full dose BCG plus short term maintenance. Patients receive a full dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, and 12.

  • Regimen 3: One third dose BCG plus long term maintenance. Patients receive a one third dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36.

  • Regimen 4: Full dose BCG plus long term maintenance. Patients receive a full dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30, and 36.

The patient is followed every 3 months for the first 3 years, and every 6 months thereafter.

Trial Contact Information

Trial Lead Organizations

European Organization for Research and Treatment of Cancer

A. Van Der Meijden, MD, PhD, Study coordinator(Contact information may not be current)

ONCOTICE LP.INVES.L 2-8x100.000.000MG CFU (12.5+3.0)MG/VIAL BT 1VIAL

疾病特征:


组织学证实为移行细胞癌,膀胱以下几种类型:
多个(不大于10),可切除,T1或Ta,G1-G3级
孤T1 GII​​I肿瘤

之前/同时治疗:

生物疗法:

事先没有与BCG治疗
化疗:

在过去3个月内无细胞生长抑制剂
内分泌治疗:

未指定
放射治疗:

未指定
手术治疗:

未指定

病人的特点:

年龄:

85及以下


治疗方案概述

这是一项前瞻性随机对照研究。

在经尿道前列腺切除后7-15天,患者开始接受以下四个方案:

方案1:第三剂量卡介苗(BCG)疫苗加短期的维护。患者接受一个第三剂BCG注入了每周一次,共6周,随后由每周三班灌注在个月内3,6,和12。

方案2:全剂量卡介苗加短期的维护。患者接受全剂量的卡介苗注入了为期6周,每周一次,由每周三班灌注3,6,和12个月时。

方案3:第三次接种卡介苗加长期维护。患者接受的三分之一,每周一次,6个月内3,6,12,18,24,30和36周,随后由每周三班灌注BCG灌注剂量。

方案4:全剂量卡介苗加长期维护。患者接受全剂量的卡介苗注入了每周一次的6个月内3,6,12,18,24,30,和36周,随后由每周三班灌注。

病人每3个月的第3年,此后每6个月。

责任编辑:admin


相关文章
B型脑膜炎球菌疫苗Bexsero获美国批准上市
Eutravac(DTaP-HepB vaccine)
Euforvac(DTwp-HepB vaccine)注射液
脑癌疫苗DCVax-Brain(vaccine for brain cancer)
流感病毒疫苗肌肉注射|Afluria(Influenza Virus Vaccine)
流感病毒疫苗|Influvac(Influenza Virus Vaccine)
爱阁力保(流感病毒疫苗)|Agrippal(Influenza Virus Vaccine)
流感病毒疫苗注射剂|Begrivac(Influenza Virus Vaccine)
Priorix(Measles,Mumps and Rubella Vaccine)疫苗
Afluria (Influenza Virus Vaccine)
 

最新文章

更多

· XOFIGO(RADIUM RA-223 D...
· Bicalutamide Tab(Bical...
· Jevtana(Cabazitaxel In...
· Lutrate DEPOT(leuproli...
· TEPADINA powder Inject...
· ESTRACYT Inj(磷酸雌莫...
· 恩杂鲁胺胶囊|Xtandi ca...
· ZYTIGA tablets(abirat...
· Busulfex injection(白...
· 卡巴他赛丙酮注射剂|jev...

推荐文章

更多

· XOFIGO(RADIUM RA-223 D...
· Bicalutamide Tab(Bical...
· Jevtana(Cabazitaxel In...
· Lutrate DEPOT(leuproli...
· TEPADINA powder Inject...
· ESTRACYT Inj(磷酸雌莫...
· 恩杂鲁胺胶囊|Xtandi ca...
· ZYTIGA tablets(abirat...
· Busulfex injection(白...
· 卡巴他赛丙酮注射剂|jev...

热点文章

更多